drugset / Trial / NCT00885495

Darunavir/Ritonavir and Rosuvastatin Pharmacokinetic Study

NCT00885495

Phase 1/2 Completed 17 enrolled University of Cincinnati
RandomizedCrossoverOpen-labelTreatment

Summary

This is a phase I, open-label, controlled drug interaction study to determine the effects of darunavir plus ritonavir on the pharmacokinetics of the hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, rosuvastatin, in HIV-1-seronegative subjects.

Timeline

Start
2009-01
Primary completion
2010-04
Completion
2010-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator Darunavir Small molecule 600 mg
Comparator Ritonavir Other / unclassified 100 mg
Comparator Rosuvastatin Small molecule 10 mg